National Institute for Health and Care Excellence

Board meeting

22 July 2022

Title

Integrated performance report

Purpose of paper

For discussion

Board action required

The Board is asked to review the report.

Brief summary

This report provides an update to the Board on the performance against our key performance indicators for the period 1 April 2022 to 31 May 2022, and a summary of progress with the objectives in the 2022/23 business plan.

* Business plan priority 1 is rated green and stable; priorities 2 and 4 are amber and stable; while priority 3 is rated amber with a downward trend.
* The majority of guidance programmes expect to deliver the volume of outputs in the 2022/23 business plan. The transition of HealthTechConnect to the Innovation service has resulted in a decrease in the number of topics in the medtech pipeline. Due to this, the medical technologies programme expect to publish 7 pieces of guidance compared to 8 in the business plan. The programme will also publish up to 5 Early Value Assessments (EVA) as part of business plan priority 3. External engagement and the development of the Topic Intelligence hub in NICE is intended to mitigate the risk to the topic pipeline in the future and ensure topics are more closely linked with NHS need. The number of quality standard alignments and medtech innovation briefings is also behind plan, but expected to catch-up later in the year.
* After the caveats that are applied to take account of factors outside of NICE's control, the targets for enabling timely access to new technologies through our TA and HST programmes were met. We are looking at how in future to demonstrate the impact of these caveats on performance.
* Sickness absence is below target and reduced between April and May. However the vacancy rate increased and staff turnover remains above plan; we are closely monitoring turnover for any trends and also reviewing exit data.
* The financial position at the end of month 2 is an underspend of £348k. Additional information on the financial performance of the technology appraisal (TA) and highly specialised technologies (HST) programmes has been provided as an appendix to this report, following a request for more information at the previous board meeting.

Board sponsor

Jennifer Howells, Director, Finance, Strategy and Transformation